Objective:To investigate the relationship between changes of serum C1q tumor necrosis factor related protein(CTRP)3, CTRP9 and vascular calcification(VC) in chronic kidney disease stage 5(CKD-Ⅴ) patients with diabetic nephropathy(DN).Methods:72 CKD-Ⅴ patients with DN(case group) and 72 cases of health examinees(control group) in Xidian Group Hospital from July 2016 to July 2018 were selected. The case group was further divided into non-vascular calcification group(n=49) and vascular calcification group(n=23) according to chest X-ray results. Serum CTRP3 and CTRP9 were determined by double-antibody sandwich enzyme combined with immunosorbent assay. One-way analysis of variance was used to compare the differences of serum CTRP3 and CTRP9 in three groups. Multivariate logistic stepwise regression analysis was used to explore the risk factors of vascular calcification in CKD-Ⅴ patients with DN.Results:The levels of CTRP3 and CTRP9 had statistic differences among the three groups(P<0.05), which ranked in a descending order was control group, non-calcification group and calcification group(P<0.05). Univariate analysis testing by χ2 showed that factors influencing vascular calcification including age, serum CTRP3, CTRP9, TC and LDL-C were statistically significant(P<0.05). Logistic stepwise regression analysis showed that patients aged<46 years, TC<5.83 ng·ml-1, and LDL-C<3.45 mmol·L-1 were protective factors for vascular calcification in CKD-Ⅴ patients with DN, while patents with CTRP3<0.78 ng·ml-1, CTRP9<10.47 ng·ml-1 were risk factors for CKD-Ⅴ patients with DN.Conclusion:Serum CTRP3 and CTRP9 may have anti-vascular calcification effect, so the elevated levels of two indicators are protective factors of vascular calcification in CKD-Ⅴ patients with DN. |
[1] 赵莎莎,高超,陶凌.脂肪因子CTRP3的认识及研究现状[J].心脏杂志,2016,28(3):341-343,361.
[2] 于思明,张显龙.中医药防治血管钙化的研究进展[J].中西医结合心脑血管病杂志,2017,15(18):2260-2263.
[3] YANG Y,LI Y,MA Z,et al.A brief glimpse at CTRP3 and CTRP9 in lipid metabolism and cardiovascular protection[J].Prog Lipid Res,2016,64(1):170-177.
[4] 贾昊,武婷,马琴,等.C1q肿瘤坏死因子相关蛋白家族代谢功能的研究进展[J].中国医师杂志,2016,18(s1):223-225.
[5] 中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识(2014年版)[J].中华糖尿病杂志,2014,6(11):792-801.
[6] 安玉,吴燕.糖尿病肾病新病理分型及其临床价值[J].中国实用内科杂志,2017,37(3):199-202.
[7] 过伟锋,曾蒙苏.冠状动脉CT成像钙化斑块减影技术的临床应用[J].放射学实践,2016,31(10):1010-1012.
[8] 王清,谢春明,张志珺.糖尿病与阿尔茨海默病关系的研究进展[J].东南大学学报(医学版),2018,37(3):510-514.
[9] 蔡士铭,赵慧萍,武蓓,等.维持性腹膜透析患者血管钙化的发生情况及其相关因素研究[J].中国血液净化,2018,27(1):19-24.
[10] 李新宇,杨栋民,吕凤清.透析3年以上不同分期慢性肾脏病患者骨代谢标志物水平检测的临床意义[J].山西医药杂志,2017,46(16):2016-2018.
[11] 王中群,戴俏武,邵晨,等.血管钙化的骨调控机制新进展[J].中华心血管病杂志,2017,45(1):9.
[12] 陈忠辉,何静.维持性血液透析患者血管钙化相关因素研究[J].蚌埠医学院学报,2016,41(9):1207-1210.
[13] WANG X Q,LIU Z H,XUE L,et al.C1q/TNF-related protein 1 links macrophage lipid metabolism to inflammation and atherosclerosis[J].Atherosclerosis,2016,250:38-45.
[14] WANG H,WANG R, DU D,et al.Serum levels of C1q/TNF-related protein-1(CTRP-1) are closely associated with coronary artery disease[J].Bmc Cardiovasc Disord,2016,16:92.
[15] 王丽萍,宋斌,戴燕,等.多种脂源性细胞因子与2型糖尿病患者胰岛素抵抗相关[J].基础医学与临床,2017,37(9):1247-1250.
[16] 薛丹,刘剑.CTRP3在糖脂代谢及心血管保护作用中的研究进展[J].心血管病学进展,2018,29(3):63-65.
[17] 林佳乐,侯静波.C1q/肿瘤坏死因子相关蛋白9与心血管疾病关系的研究进展[J].心肺血管病杂志,2016,35(7):588-590. |